Novel kif18a inhibitors for treating cancer
WebFeb 22, 2024 · KIF18A is required for proliferation of CIN cells derived from triple negative breast cancer or colorectal cancer tumors but is not required in near-diploid cells. Following KIF18A... WebMay 28, 2024 · TPS5600 Background: KIF18A is a mitotic kinesin motor protein that regulates chromosome positioning during cell division and is overexpressed in a subset of human cancers. TP53 mutant unstable aneuploid cancer cells with chromosomal instability (CIN) features are dependent on KIF18A motor activity to prevent lethal multipolar cell …
Novel kif18a inhibitors for treating cancer
Did you know?
WebSep 9, 2024 · Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer’s most ... WebMar 28, 2024 · A plethora of novel endocrine and biologic treatment options are finally filling the gap between first-line ET and later line chemotherapy, and the activity of these novel treatment options and their potential role in future treatment algorithms are recapitulate. Simple Summary There are limited treatment options beyond chemotherapy for patients …
WebMonopolar spindle kinase 1 (Mps1) is a key element of the mitotic checkpoint and clinically evaluated as a target in the treatment of aggressive tumors. With this aim, a set of pyrazolo[3,4-b]pyridine-based compounds as new Mps1 inhibitors was investigated through a multidisciplinary approach, based … WebSep 9, 2024 · Volastra Therapeutics, an oncology company focused on exploiting chromosomal instability (CIN), today announced new data from its lead program, a KIF18A inhibitor, validating its therapeutic...
WebNov 19, 2024 · KIF18A appears to be a viable target for the treatment of cancer. KIF18A is overexpressed in various types of cancers, including but not limited to colon, breast, lung, … WebSep 4, 2024 · KIF18A appears to be a viable target for the treatment of cancer. KIF18A is overexpressed in various types of cancers, including but not limited to colon, breast, lung, …
National Center for Biotechnology Information
WebMar 7, 2024 · Volastra Therapeutics announced Tuesday it has in-licensed Amgen’s Phase I candidate sovilnesib, a KIF18A inhibitor being studied for high-grade ovarian cancer, triple … security military depot indiana paWebPublication Publication Date Title. EA202490912A1 2024-10-31 ANTI-LAG-3 ANTIBODIES AND THEIR COMPOSITIONS. CR20240387A 2024-08-19 Kif18a inhibitors. PH12024501350A1 2024-01-20 Amino-triazolopyridine compounds and their use in treating cancer. PH12024502870A1 2024-09-28 Small molecule modulators of human sting. security mobility e3WebSep 29, 2024 · The data are highly encouraging, as they showed treatment with our KIF18A inhibitor led to substantial, dose-dependent inhibition of tumor growth in lung and ovarian … pursue the trendWebSep 9, 2024 · Treatment with KIF18A inhibitor led to substantial, dose-dependent inhibition of tumor growth in multiple tumor models, with no effect on normal cells KIF18A inhibitor on track to enter the clinic in 2H 2024 pursue the tierna harh cadachtasWebMar 7, 2024 · Volastra Therapeutics announced Tuesday it has in-licensed Amgen’s Phase I candidate sovilnesib, a KIF18A inhibitor being studied for high-grade ovarian cancer, triple-negative breast cancer and other solid tumors. Concurrently, the New York-based biotech has secured $60 million in Series A funding. The financing round was led by Eli Lilly ... security mnsuWebMar 29, 2024 · Selective and ATP-competitive kinesin KIF18A inhibitor suppresses the replication of influenza A virus. KIF18A knockdown reduces proliferation, migration, invasion and enhances radiosensitivity of esophageal cancer. Kinesin KIF18A is a novel PUM-regulated target promoting mitotic progression and survival of a human male germ cell line. security mod 1.12.2 curseforgeWebMar 7, 2024 · Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline Financing led by founding investors... pursue the path